Effect of Grapefruit Pulp on the Pharmacokinetics of the Dihydropyridine Calcium Antagonists Nifedipine and Nisoldipine

Bibliographic Information

Other Title
  • グレープフルーツ果肉部分摂取時によるジヒドロピリジン系Ca拮抗薬ニフェジピン及びニソルジピンの薬物動態への影響
  • グレープフルーツ カニク ブブン セッシュジ ニ ヨル ジヒドロピリジンケイ Ca キッコウヤク ニフェジピン オヨビ ニソルジピン ノ ヤクブツ ドウタイ エ ノ エイキョウ

Search this article

Description

The effect of the intake of 200g of grapefruit pulp (corresponding to one grapefruit) on the pharmacokinetics of the calcium antagonists nifedipine (NF) and nisoldipine (NS) were investigated in 8 healthy Japanese male volunteers. A crossover design was used for the study: group I did not ingest any grapefruit (control group); group II ingested grapefruit 1 h after drug administration; and group III ingested grapefruit 1 h before drug administration. The intake of grapefruit pulp increased the plasma concentrations of both NF and NS, an effect that has previously been reported with grapefruit juice. The increase was most marked when grapefruit was eaten before drug administration. For both NF and NS, subjects who ingested grapefruit 1 h before drug administration exhibited a greater Cmax and AUC0—24 than did subjects in the control group. For NF, the Cmax was 1.4 times higher and the AUC0—24 1.3 times larger in group III than in group I. For NS, the Cmax was 1.5 times higher and the AUC0—24 1.3 times larger in group III than in group I. The increase in the AUC0-24 was significant for both drugs (p<0.05). The finding that the ratios of Cmax and AUC0—24 for unchanged drug and metabolites did not vary greatly among the three groups for either drug suggests that the increase in serum concentration produced by grapefruit intake may be due to other factors than an inhibitory effect on drug metabolism. Also, the increases in Cmax and AUC0—24 of NS produced by grapefruit intake were smaller than those produced by grapefruit juice intake, indicating that grapefruit pulp and juice have different effects on the pharmacokinetics.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 122 (5), 323-329, 2002-05-01

    The Pharmaceutical Society of Japan

Citations (3)*help

See more

References(34)*help

See more

Details 詳細情報について

Report a problem

Back to top